Paulson, Daniel M <br/><br/>
Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial.  [electronic resource] 

 -  The journal of pain  Mar 2005 
 - 184-92 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1526-5900 
<br/><br/><label>Standard No.: </label>10.1016/j.jpain.2004.12.001  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Analgesics, Opioid--adverse effects<br/>Cathartics--administration & dosage<br/>Chronic Disease<br/>Constipation--chemically induced<br/>Female<br/>Follow-Up Studies<br/>Gastrointestinal Motility--drug effects<br/>Humans<br/>Male<br/>Middle Aged<br/>Pain--drug therapy<br/>Piperidines--administration & dosage<br/>Receptors, Opioid, mu--antagonists & inhibitors<br/>Treatment Outcome